Update on XenoPort's Horizant - Analyst Blog

By
A A A

XenoPort, Inc. ( XNPT ) recently announced that gabapentin enacarbil, which is the active ingredient in Horizant, has been included in an updated treatment algorithm as an initial therapy for patients with chronic persistent restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Wed Foundation's algorithm was published in the current Mayo Clinic Proceedings issue.

Horizant is approved in the U.S. for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as the management of postherpetic neuralgia (PHN) in adults.

In Jul 2013, Horizant was also included by the Task Force of the International Restless Legs Syndrome Study Group in their new treatment guidelines as a first-line treatment for RLS/WED. The guidelines bode well for Horizant.

In May 2013, XenoPort resumed the supply and shipment of Horizant. The company was also successful in resolving manufacturing issues and expects to fill in orders from wholesalers. We note that GlaxoSmithKline ( GSK ) faced manufacturing delays of Horizant in the U.S., leading to product shortage.

We remind investors that Glaxo and XenoPort had a collaboration agreement for Horizant that was terminated in Nov 2012. Glaxo had commercialization rights to the drug through the transition period, which ended on Apr 30, 2013. On May 1, 2013, XenoPort re-acquired all commercialization rights to Horizant. Glaxo, however, is expected to supply Horizant to XenoPort until Oct 30, 2013.

XenoPort carries a Zacks Rank #3 (Hold). Currently, companies which look attractive include Actelion Ltd. ( ALIOF ) and Jazz Pharmaceuticals ( JAZZ ) with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively.



ACTELION LTD (ALIOF): Get Free Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

XENOPORT INC (XNPT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , GSK , JAZZ , RLS , XNPT

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com